<DOC>
	<DOCNO>NCT02748993</DOCNO>
	<brief_summary>This phase 1 2 study ass safety efficacy PAC-14028 cream child atopic dermatitis .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy PAC-14028 Cream Pediatric Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female patient age 24 month 12 year Who diagnose Atopic Dermatitis accord Haniffin Rajka criterion , whose affect BSA 5 % IGA score 2 ( mild ) 3 ( moderate ) . Who apply stable amount emollient daily baseline visit Who voluntarily agree participate study sign informed consent form . Who skin disease atopic dermatitis scar affect area affect study , determine study investigator . Who clinically significant medical history disease involve liver , kidney , neurological system , psychial disorder affect study result . Who use systemic steroid , antibiotic , immunosuppressant , receive photochemical therapy within 28 day study drug administration . Who use topical steroid , immunosuppressant antibiotic treat atopic dermatitis within 14 day study drug administration . Who use expect inevitably use prohibited concomitant medication study . Women pregnant /breastfeeding , childbearing potential use available contraceptive . Who dose study medication within 30 day screen . Who determine ineligible study participation investigator reason .</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>